Rhythm Pharmaceuticals TRANSCEND trial results published in NEJM

July 8, 2026 5:07 PM

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced that results from its Phase 3 TRANSCEND trial evaluating setmelanotide in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found